Peptides of syndecan-1 for inhibiting angiogenesis
The present invention provides a peptide derived from the extracellular domain of syndecan-1 that inhibits angiogenesis.
1. A method of inhibiting αvβ 3 or αvβ 5 integrin activation by syndecan-1, comprising contacting a cell expressing an αvβ 3 or αvβ 5 integrin molecule with a polypeptide segment consisting of 32 to 100 amino acid residues and comprising SEQ ID NO:21, whereby the αvβ 3 or αvβ 5 integrin activation is inhibited.
2. The method of claim 1 , wherein the polypeptide segment is 32 to 80 amino acid residues in length.
3. The method of claim 1 , wherein the polypeptide segment is 32 to 50 amino acid residues in length.
4. The method of claim 1 , wherein the polypeptide segment consists of SEQ ID NO:10.
5. The method of claim 1 , wherein the polypeptide segment comprises at least 35 contiguous amino acids from SEQ ID NO:10.
6. The method of claim 1 , wherein the polypeptide segment consists of SEQ ID NO:28.
7. The method of claim 1 , wherein the polypeptide segment consists of SEQ ID NO:21.
8. The method of claim 1 , wherein the step of contacting the cell with the polypeptide segment is accomplished by administering the polypeptide segment to a subject having a disease characterized by the activation of the αvβ 3 or αvβ 5 integrin, whereby the disease is treated.
9. The method of claim 8 , wherein the disease is a cancer in which the αvβ 3 or αvβ 5 integrin is upregulated.
10. The method of claim 9 , wherein the method inhibits the survival of cancerous tumor cells within the subject.
11. The method of claim 10 , wherein survival of the cancerous tumor cells is inhibited by inducing apoptosis in the cancerous tumor cells.
12. The method of claim 9 , wherein the method inhibits the migration of cancerous tumor cells within the subject.
13. The method of claim 9 , wherein the method inhibits the metastasis of cancerous tumor cells within the subject.
14. The method of claim 9 , wherein the method inhibits cancer-related angiogenesis within the subject.
15. The method of claim 14 , wherein the angiogenesis is inhibited by reducing the proliferation and migration of endothelial cells that are associated with angiogenesis.
16. The method of claim 14 , wherein the angiogenesis is inhibited by reducing the survival of endothelial cells that are associated with angiogenesis.
17. The method of claim 16 , wherein survival of the endothelial cells is reduced by increasing the susceptibility of the endothelial cells to apoptosis.
18. The method of claim 8 , wherein the disease is a noncancerous disease in which the αvβ 3 or αvβ 5 integrin is upregulated.
19. The method of claim 18 , wherein the noncancerous disease is a disease that is characterized by angiogenesis.
20. The method of claim 19 , wherein the method inhibits the disease-related angiogenesis within the subject.